{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:16:45Z","timestamp":1787494605773,"version":"build-2736575974"},"reference-count":38,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T00:00:00Z","timestamp":1666051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Ministry of Education, Culture, Sports, Science and Technology of Japan","award":["22K08770"],"award-info":[{"award-number":["22K08770"]}]},{"name":"Ministry of Education, Culture, Sports, Science and Technology of Japan","award":["22K15604"],"award-info":[{"award-number":["22K15604"]}]},{"name":"The NOVARTIS Foundation (Japan)","award":["22K08770"],"award-info":[{"award-number":["22K08770"]}]},{"name":"The NOVARTIS Foundation (Japan)","award":["22K15604"],"award-info":[{"award-number":["22K15604"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>Reprogramming of energy metabolism is regarded as one of the hallmarks of cancer; in particular, oncogenic RAS has been shown to be a critical regulator of cancer metabolism. Recently, asparagine metabolism has been heavily investigated as a novel target for cancer treatment. For example, Knott et al. showed that asparagine bioavailability governs metastasis in a breast cancer model. Gwinn et al. reported the therapeutic vulnerability of asparagine biosynthesis in KRAS-driven non-small cell lung cancer. We previously reported that KRAS-mutated CRC cells can adapt to glutamine depletion through upregulation of asparagine synthetase (ASNS), an enzyme that synthesizes asparagine from aspartate. In our previous study, we assessed the efficacy of asparagine depletion using human cancer cell lines. In the present study, we evaluated the clinical relevance of asparagine depletion using a novel patient-derived spheroid xenograft (PDSX) mouse model. First, we examined ASNS expression in 38 spheroid lines and found that 12 lines (12\/37, 32.4%) displayed high ASNS expression, whereas 26 lines (25\/37, 67.6%) showed no ASNS expression. Next, to determine the role of asparagine metabolism in tumor growth, we established ASNS-knockdown spheroid lines using lentiviral short hairpin RNA constructs targeting ASNS. An in vitro cell proliferation assay demonstrated a significant decrease in cell proliferation upon asparagine depletion in the ASNS-knockdown spheroid lines, and this was not observed in the control spheroids lines. In addition, we examined asparagine inhibition with the anti-leukemia drug L-asparaginase (L-Asp) and observed a considerable reduction in cell proliferation at a low concentration (0.1 U\/mL) in the ASNS-knockdown spheroid lines, whereas it exhibited limited inhibition of control spheroid lines at the same concentration. Finally, we used the PDSX model to assess the effects of asparagine depletion on tumor growth in vivo. The nude mice injected with ASNS-knockdown or control spheroid lines were administered with L-Asp once a day for 28 days. Surprisingly, in mice injected with ASNS-knockdown spheroids, the administration of L-Asp dramatically inhibited tumor engraftment. On the other hands, in mice injected with control spheroids, the administration of L-Asp had no effect on tumor growth inhibition at all. These results suggest that ASNS inhibition could be critical in targeting asparagine metabolism in cancers.<\/jats:p>","DOI":"10.3390\/cells11203273","type":"journal-article","created":{"date-parts":[[2022,10,18]],"date-time":"2022-10-18T21:18:02Z","timestamp":1666127882000},"page":"3273","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Targeting Asparagine Synthetase in Tumorgenicity Using Patient-Derived Tumor-Initiating Cells"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4223-8482","authenticated-orcid":false,"given":"Gen","family":"Nishikawa","sequence":"first","affiliation":[{"name":"Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"},{"name":"Department of Surgery, Kyoto City Hospital, Kyoto 604-8845, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4336-6937","authenticated-orcid":false,"given":"Kenji","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Hanada","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"},{"name":"Department of Surgery, Rakuwakai Otowa Hospital, Kyoto 607-8062, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisatsugu","family":"Maekawa","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7356-7065","authenticated-orcid":false,"given":"Yoshiro","family":"Itatani","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Miyoshi","sequence":"additional","affiliation":[{"name":"Institute for Advancement of Clinical and Translational Science (IACT), Kyoto University Hospital, Kyoto 606-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9032-4505","authenticated-orcid":false,"given":"Makoto Mark","family":"Taketo","sequence":"additional","affiliation":[{"name":"Institute for Advancement of Clinical and Translational Science (IACT), Kyoto University Hospital, Kyoto 606-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2924-6701","authenticated-orcid":false,"given":"Kazutaka","family":"Obama","sequence":"additional","affiliation":[{"name":"Department of Gastrointestinal Surgery, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1126\/science.aam7622","article-title":"Drugging RAS: Know the enemy","volume":"355","author":"Papke","year":"2017","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrm2438","article-title":"Ras oncogenes: Split personalities","volume":"9","author":"Karnoub","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/1947601911412376","article-title":"Therapeutic strategies for targeting ras proteins","volume":"2","author":"Gysin","year":"2011","journal-title":"Genes Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s10147-017-1156-4","article-title":"Targeting metabolic reprogramming in KRAS-driven cancers","volume":"22","author":"Kawada","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1056\/NEJMoa0804385","article-title":"K-ras mutations and benefit from cetuximab in advanced colorectal cancer","volume":"359","author":"Karapetis","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/nature11156","article-title":"Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer","volume":"486","author":"Misale","year":"2012","journal-title":"Nature"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1200\/JCO.2008.20.8397","article-title":"Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer","volume":"27","author":"Bokemeyer","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1126\/science.1160809","article-title":"Understanding the Warburg effect: The metabolic requirements of cell proliferation","volume":"324","author":"Cantley","year":"2009","journal-title":"Science"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg\u2019s contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/nrc2981","article-title":"Regulation of cancer cell metabolism","volume":"11","author":"Cairns","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/nrd4145","article-title":"Metabolic targets for cancer therapy","volume":"12","author":"Galluzzi","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/nature12138","article-title":"Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells","volume":"497","author":"Commisso","year":"2013","journal-title":"Nature"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1101\/gad.2016311","article-title":"Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis","volume":"25","author":"Guo","year":"2011","journal-title":"Genes Dev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.canlet.2021.09.023","article-title":"Dual blockade of macropinocytosis and asparagine bioavailability shows synergistic anti-tumor effects on KRAS-mutant colorectal cancer","volume":"522","author":"Hanada","year":"2021","journal-title":"Cancer Lett."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1126\/science.1174229","article-title":"Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells","volume":"325","author":"Yun","year":"2009","journal-title":"Science"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","article-title":"Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism","volume":"149","author":"Ying","year":"2012","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/1078-0432.CCR-11-1909","article-title":"Relationship between 18F-fluorodeoxyglucose accumulation and KRAS\/BRAF mutations in colorectal cancer","volume":"18","author":"Kawada","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.2967\/jnumed.114.142927","article-title":"Regulation of 18F-FDG accumulation in colorectal cancer cells with mutated KRAS","volume":"55","author":"Iwamoto","year":"2014","journal-title":"J. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.tibs.2010.05.003","article-title":"Glutamine addiction: A new therapeutic target in cancer","volume":"35","author":"Wise","year":"2010","journal-title":"Trends Biochem. Sci."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature12040","article-title":"Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway","volume":"496","author":"Son","year":"2013","journal-title":"Nature"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/onc.2009.358","article-title":"Q\u2019s next: The diverse functions of glutamine in metabolism, cell biology, and cancer","volume":"29","author":"DeBerardinis","year":"2010","journal-title":"Oncogene"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.neo.2016.09.004","article-title":"Metabolic Alterations Caused by KRAS Mutations in Colorectal Cancer Contribute to Cell Adaptation to Glutamine Depletion by Upregulation of Asparagine Synthetase","volume":"18","author":"Toda","year":"2016","journal-title":"Neoplasia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature25465","article-title":"Asparagine bioavailability governs metastasis in a model of breast cancer","volume":"554","author":"Knott","year":"2018","journal-title":"Nature"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.ccell.2017.12.003","article-title":"Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-Asparaginase","volume":"33","author":"Gwinn","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2018.04.012","article-title":"Asparagine and Glutamine: Co-conspirators Fueling Metastasis","volume":"27","author":"Luo","year":"2018","journal-title":"Cell Metab."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1038\/nprot.2013.153","article-title":"In vitro expansion and genetic modification of gastrointestinal stem cells in spheroid culture","volume":"8","author":"Miyoshi","year":"2013","journal-title":"Nat. Protoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"21950","DOI":"10.18632\/oncotarget.25134","article-title":"An improved method for culturing patient-derived colorectal cancer spheroids","volume":"9","author":"Miyoshi","year":"2018","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/1535-7163.MCT-18-0128","article-title":"A Chemosensitivity Study of Colorectal Cancer Using Xenografts of Patient-Derived Tumor-Initiating Cells","volume":"17","author":"Maekawa","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.molcel.2014.08.018","article-title":"Asparagine plays a critical role in regulating cellular adaptation to glutamine depletion","volume":"56","author":"Zhang","year":"2014","journal-title":"Mol. Cell."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cmet.2017.12.006","article-title":"As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid","volume":"27","author":"Pavlova","year":"2018","journal-title":"Cell Metab."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"11457","DOI":"10.1038\/ncomms11457","article-title":"Asparagine promotes cancer cell proliferation through use as an amino acid exchange factor","volume":"7","author":"Krall","year":"2016","journal-title":"Nat. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.1016\/j.bmc.2012.07.047","article-title":"A sulfoximine-based inhibitor of human asparagine synthetase kills L-asparaginase-resistant leukemia cells","volume":"20","author":"Ikeuchi","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"E7776-e85","DOI":"10.1073\/pnas.1805523115","article-title":"Inhibition of GCN2 sensitizes ASNS-low cancer cells to asparaginase by disrupting the amino acid response","volume":"115","author":"Nakamura","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2015.07.017","article-title":"Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells","volume":"162","author":"Sullivan","year":"2015","journal-title":"Cell"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41556-018-0118-z","article-title":"Aspartate is a limiting metabolite for cancer cell proliferation under hypoxia and in tumours","volume":"20","author":"Baudrier","year":"2018","journal-title":"Nat. Cell Biol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/20\/3273\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:56:13Z","timestamp":1760144173000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/11\/20\/3273"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,18]]},"references-count":38,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cells11203273"],"URL":"https:\/\/doi.org\/10.3390\/cells11203273","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,18]]}}}